We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
As the 118th Congress continues, FDAnews will track important pending legislation to keep you updated on regulations that could impact your business. Read More
This week, three medical devices used for cardiac issues were deemed class I by the FDA, the most serious type of recall, as use of the device may cause serious injury or death. Read More
HHS announced plans to issue several FDA-related proposed and final rules in the coming year in its semiannual inventory of rulemaking actions. Read More
Over the past week, the FDA issued final guidance for deoxyribonucleic acid (DNA) reactive impurities in pharmaceuticals, assessing biosimilar user fees, hydrogen peroxide-based contact lens products and CDER’s program for the recognition of voluntary consensus standards guidance on medical device development tools. The FDA 2024 user fees were also announced. Read More
While prescription drug user fees increased a hefty 19.9 percent and medical device fees a modest 8.7, fees for biosimilar applications dropped up to an eye-popping 373 percent. Read More
Recommendations for study design to facilitate innovation in development of devices, such as deep brain, transcranial magnetic and spinal cord stimulations, intended to treat opioid use disorder (OUD) are the subject of a draft guidance issued July 27. Read More
More than 20 billion devices are sterilized with EtO each year, CDRH says, representing about 50 percent of devices that require sterilization. Read More
AdvaMed and Deloitte have updated their 2017 report on assessing the value of diagnostic technologies by incorporating a look at how the shift of risk from payer to provider will affect the adoption of new medtech innovations — while at the same time, reducing cost, improving patient experience, outcomes and satisfaction. Read More
Helping consumers avoid adverse events from improper use of hydrogen peroxide-based contact lens care products (HPCP) by improving labeling is the aim of a final guidance the FDA released Wednesday. Read More